Can immunotherapy cause erectile dysfunction?

Immunotherapy itself is not a common direct cause of erectile dysfunction (ED), but it can indirectly contribute through hormonal (endocrine) side effects and overall cancer-related factors. ED is well recognized after many cancer treatments, especially prostate surgery, radiation, and hormone therapy, and can also arise from treatment-related changes to nerves, blood vessels, and hormones. ^{[1] [2] [3]} ED may also result from decreased testosterone (hypogonadism) after certain cancer therapies or transplants, which can reduce libido and erections. ^{[4] [5]}

---

How immunotherapy may lead to ED

• Endocrine immune-related effects: Immune checkpoint inhibitors can inflame endocrine organs (like the pituitary hypophysitis or testes orchitis), potentially lowering testosterone. Limited evidence suggests immune checkpoint inhibitor–related hypogonadism from orchitis or hypophysitis, which can impair sexual function. ^[6] Similar cautions are noted across regimens combining chemotherapy with checkpoint inhibitors, where fertility and sex hormones can be affected. ^{[7] [8] [9]}

• Cancer and treatment burden: Fatigue, mood changes, and vascular risk factors related to cancer and its therapies can make achieving and maintaining erections harder. ^[3] Men with cancers historically linked to smoking (head and neck, lung) are at increased risk for ED due to vascular damage from tobacco exposure. ^{[10] [11]}

• Radiation and surgery history: If you’ve had pelvic radiation or prostate surgery along with immunotherapy, nerve and vascular injury from those treatments can be primary drivers of ED, sometimes appearing months to years later. ^{[1] [2]}

---

Recognizing warning signs

• New erectile difficulty or loss of libido: This may signal low testosterone or other endocrine issues after treatment. Decreased testosterone has been observed after certain cancer treatments and transplants and can cause ED and reduced sexual desire. ^{[4] [5]}

• Other endocrine symptoms: Headaches, vision changes, fatigue, cold intolerance, or testicular pain may suggest pituitary or testicular inflammation. Healthcare teams recommend discussing fertility and hormonal risks before starting immune checkpoint inhibitors because their effects on fertility are unknown and endocrine inflammation has been reported. ^{[6] [7] [8] [9]}

---

Evidence-based coping and treatment options

• Medical evaluation first

  • Ask your team to check cardiovascular risks (blood pressure, lipids), diabetes control, smoking status, and medications that may worsen ED. Addressing modifiable risks is the first step in ED care models used in cancer centers. ^{[12] [13] [14] [15]}
  • Consider endocrine workup (testosterone, LH/FSH, prolactin, thyroid, cortisol, and pituitary function) if symptoms suggest hormone imbalance. Endocrine immune effects are uncommon but recognized and may need specialist evaluation. ^{[6] [16]}

• First-line ED therapies

  • PDE5 inhibitors (sildenafil/Viagra, vardenafil/Levitra, tadalafil/Cialis) are commonly used first and show good response rates in cancer-related ED. ^{[12] [13] [14] [15]}
  • If pills are not effective or suitable, vacuum erection devices, penile injections, or urethral suppositories can be considered. ^{[17] [3]}

• Hormone management

  • If low testosterone is confirmed and safe to treat (not contraindicated by cancer type), discuss testosterone replacement risks and benefits with your oncologist and endocrinologist. Low testosterone states after cancer treatment can contribute to ED and loss of libido. ^{[4] [5]}

• Sexual rehabilitation and counseling

  • Specialized sexual health programs help tailor a plan to minimize dysfunction after cancer treatment, involving both medical and psychosocial supports. ^[2] Addressing relationship dynamics and stress is part of comprehensive ED care models. ^{[12] [14] [15]}

• Lifestyle supports

  • Smoking cessation, regular exercise, weight management, and control of blood pressure and cholesterol can improve erections and overall sexual health. ^{[12] [14] [15]}
  • Use lubricants and consider timing sexual activity when energy is highest, since fatigue from treatment can affect performance. Cancer care teams can also recommend practical aids and medicines for sexual function. ^[3]

---

When to contact your care team

• Sudden or worsening ED, loss of libido, or testicular/pituitary symptoms (headache, visual changes, severe fatigue) should prompt evaluation for possible endocrine immune-related adverse events. Clinicians highlight that while data are limited, checkpoint inhibitors can rarely cause hormone-related issues affecting sexual function and fertility. ^{[6] [7] [8] [9]}

---

Quick reference: ED after cancer treatment

Topic	Key points
Common causes	Prostate surgery, radiation, hormone therapy; vascular and nerve injury; endocrine changes
Immunotherapy link	Rare, often indirect via endocrine inflammation (hypophysitis, orchitis) leading to low testosterone
First-line treatments	PDE5 inhibitors (sildenafil, vardenafil, tadalafil)
Alternatives	Vacuum devices, injections, urethral suppositories; sexual rehab programs
Workup	Cardiovascular risks, diabetes, medication review, endocrine labs if symptoms suggest hormone issues
Support	Counseling, partner involvement, lifestyle changes, specialist referral (urology/sexual medicine)

Many people find meaningful improvement when ED is approached with a combined medical, hormonal, and psychosocial plan tailored to their cancer journey. ^{[12] [14] [15] [2] [3] [17] [4] [5] [1] [10] [11]}